Clovis Oncology: Rubraca meets primary endpoint of significantly improving progression-free survival vs. chemo in cancer study

Clovis Oncology: Rubraca meets primary endpoint of significantly improving progression-free survival vs. chemo in cancer study

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed... Read More

Monday December 21, 2020 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces purchase of additional $7.5M of its 4.50% convertible senior notes due 2024

Clovis Oncology announces purchase of additional $7.5M of its 4.50% convertible senior notes due 2024

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced an existing holder of its securities relating to the offering of the company’s new series of 4.50% Convertible Senior Notes due 2024 has... Read More

Wednesday November 25, 2020 0 comments Tags: Boulder, Clovis Oncology, Rucaparib

Clovis Oncology announces new recommendations for Rubraca for treatment of metastatic castration-resistant prostate cancer

Clovis Oncology announces new recommendations for Rubraca for treatment of metastatic castration-resistant prostate cancer

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS), today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to... Read More

Friday May 29, 2020 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy

Clovis: Rucaparib recommended for United Kingdom women with relapsed ovarian cancer

Clovis: Rucaparib recommended for United Kingdom women with relapsed ovarian cancer

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have... Read More

Monday October 14, 2019 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey

Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer

Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the European Commission (EC) has approved the use of Rubraca(rucaparib) for treatment of ovarian cancer. Specifically, the... Read More

Monday January 28, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca, Rucaparib

Clovis Oncology announces positive hearing for Rubraca in Europe

Clovis Oncology announces positive hearing for Rubraca in Europe

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More

Wednesday December 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, Rucaparib

Clovis Oncology announces second patent for Rucaparib high dose

Clovis Oncology announces second patent for Rucaparib high dose

BOULDER -- Clovis Oncology , Inc. (NASDAQ:CLVS) today announced the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating... Read More

Tuesday November 20, 2018 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with... Read More

Tuesday May 29, 2018 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rucaparib